Man Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$25.6M Buy
135,212
+56,935
+73% +$9.95M 0.05% 404
2025
Q4
$13.3M Buy
78,277
+35,111
+81% +$5.38M 0.02% 667
2025
Q3
$5.69M Buy
43,166
+28,750
+199% +$3.45M 0.01% 1023
2025
Q2
$1.53M Sell
14,416
-3,842
-21% -$417K ﹤0.01% 1504
2025
Q1
$2.27M Sell
18,258
-8,817
-33% -$1.15M 0.01% 1318
2024
Q4
$3.33M Buy
27,075
+4,890
+22% +$576K 0.01% 1157
2024
Q3
$2.47M Buy
22,185
+9,729
+78% +$1.07M 0.01% 1249
2024
Q2
$1.33M Sell
12,456
-87,388
-88% -$9.61M ﹤0.01% 1465
2024
Q1
$12M Sell
99,844
-25,461
-20% -$3.12M 0.03% 627
2023
Q4
$15.4M Buy
+125,305
New +$15.6M 0.04% 489
2023
Q3
Sell
-33,502
Closed -$4.46M 602
2023
Q2
$4.15M Buy
+33,502
New +$4.51M 0.01% 954
2023
Q1
Sell
-30,093
Closed -$4.45M 1660
2022
Q4
$4.79M Buy
30,093
+28,388
+1,665% +$4.16M 0.02% 849
2022
Q3
$226K Buy
+1,705
New +$259K ﹤0.01% 1742
2022
Q1
Sell
-2,139
Closed -$272K 2264
2021
Q4
$272K Buy
+2,139
New +$281K ﹤0.01% 1715
2021
Q3
Sell
-11,628
Closed -$2.06M 1992
2021
Q2
$2.06M Sell
11,628
-9,886
-46% -$1.71M 0.01% 1212
2021
Q1
$3.54M Sell
21,514
-6,880
-24% -$1.13M 0.02% 862
2020
Q4
$4.69M Sell
28,394
-81,700
-74% -$12.2M 0.02% 846
2020
Q3
$15.7M Buy
110,094
+3,631
+3% +$450K 0.06% 336
2020
Q2
$11.7M Sell
106,463
-92,771
-47% -$10.3M 0.06% 309
2020
Q1
$19.9M Sell
199,234
-14,714
-7% -$1.9M 0.13% 162
2019
Q4
$31.9M Buy
213,948
+66,978
+46% +$9.11M 0.11% 227
2019
Q3
$18.8M Sell
146,970
-39,106
-21% -$5.24M 0.07% 335
2019
Q2
$26.5M Buy
186,076
+24,099
+15% +$3.24M 0.1% 257
2019
Q1
$23.2M Buy
161,977
+106,111
+190% +$13.8M 0.09% 275
2018
Q4
$6.93M Sell
55,866
-7,092
-11% -$1.05M 0.03% 605
2018
Q3
$10.6M Buy
62,958
+34,755
+123% +$5.98M 0.04% 591
2018
Q2
$4.86M Buy
28,203
+12,596
+81% +$2.06M 0.02% 960
2018
Q1
$2.36M Buy
+15,607
New +$2.29M 0.01% 1220

Other funds holding JAZZ

Man Group's JAZZ Position: Q1 2026 in Review

Man Group increased its Jazz Pharmaceuticals (JAZZ) stake by 73% in Q1 2026, buying an estimated $9.95M and bringing the position to 135,212 shares worth $25.6M. The position accounts for 0.05% of the portfolio, ranked #404.

Man Group first reported a position in JAZZ in Q1 2018 and has held it in 28 quarters since. The position peaked at $31.9M in Q4 2019. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Man Group held 135,212 shares of Jazz Pharmaceuticals worth $25.6M as of Q1 2026.
  • Man Group bought 56,935 Jazz Pharmaceuticals shares in Q1 2026, an estimated $9.95M.
  • Jazz Pharmaceuticals made up 0.05% of Man Group's portfolio in Q1 2026, its #404 holding.
  • Man Group first reported a position in Jazz Pharmaceuticals in Q1 2018 and has held it in 28 quarters since.
  • Man Group's Jazz Pharmaceuticals position peaked at $31.9M in Q4 2019.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.